Abiraterone Acetate Plus Prednisone Demonstrates OS Benefit in Prostate Cancer

Abiraterone Acetate Plus Prednisone Demonstrates OS Benefit in Prostate Cancer

An abiraterone acetate (Zytiga) plus prednisone combination showcased an 11.8-month improvement in overall survival (OS) when compared with prednisone and placebo in less advanced, chemotherapy-na├»ve metastatic castration-resistant prostate cancer …

(Visited 1 times, 1 visits today)
2
Like
Save

Comments

Comments are disabled for this post.